Curis 2025 Q1 Earnings Misses Targets with Net Loss Reduction

Curis (CRIS) reported its fiscal 2025 Q1 earnings on May 06th, 2025. Curis fell short of analyst expectations, reporting lower-than-anticipated revenue figures and earnings per share (EPS) performance. Despite missing targets, Curis provided guidance indicating continued enrollment in key studies, aiming to bolster its strategic initiatives. The company maintained a cautious outlook, emphasizing its progress in clinical trials and the potential for accelerated approvals. Investors remain watchful of Curis’s strategic moves and upcoming milestones as they assess the impact on future earnings.

Revenue

Earnings/Net Income
Curis narrowed losses to $1.25 per share in 2025 Q1 from a loss of $2.05 per share in 2024 Q1 (39.0% improvement). Meanwhile, the company successfully narrowed its net loss to $-10.62 million in 2025 Q1, reducing losses by 10.6% compared to the $-11.88 million net loss reported in 2024 Q1. This quarter's EPS performance did not meet expectations, indicating challenges in achieving profitability.

Price Action
The stock price of Curis has tumbled 9.13% during the latest trading day, has surged 20.99% during the most recent full trading week, and has surged 64.66% month-to-date.

Post-Earnings Price Action Review
Investors who employed the strategy of buying Curis shares after a revenue drop quarter-over-quarter and holding for 30 days have faced significant losses over the past five years. This strategy has proven unprofitable, as the total return for CRIS stock is -70.84% over the past 12 months, and it has decreased by 4.90% this year. These figures highlight a substantial decline in value despite the short holding period, indicating that this approach has not been successful.

CEO Commentary
Jim Dentzer, President and Chief Executive Officer, expressed optimism regarding Curis' progress, highlighting strong momentum in the TakeAim lymphoma study evaluating emavusertib in combination with ibrutinib, with expectations for accelerated submissions to the FDA and EMA. He emphasized the promising results from treating relapsed/refractory PCNSL patients, noting that nine out of 13 experienced patients showed a reduction in tumor burden. Dentzer acknowledged the importance of Dr. Ahmed Hamdy's leadership in advancing the company's strategies in primary CNS lymphoma and expanding into additional indications like NHL and AML. He conveyed a cautious yet positive outlook as the team focuses on enrolling more patients for NDA submission.

Guidance
Curis anticipates completing enrollment for the TakeAim lymphoma study within the next 12 to 18 months, targeting 30 to 40 additional patients to support the NDA submission, aiming for 6 to 8 responses in this dataset. The company expects its existing cash and cash equivalents of $20.3 million will fund operations into the fourth quarter of 2025, with a net loss projected at $10.6 million for Q1 2025.

Additional News
Curis has strengthened its executive team with the appointment of Dr. Ahmed Hamdy as Chief Medical Officer, a move expected to bolster its leadership in advancing therapeutic strategies. The company has also successfully completed a registered direct offering and concurrent private placement, raising net proceeds of approximately $8.8 million. Additionally, Curis received Orphan Drug Designation for emavusertib in both the U.S. and Europe, highlighting its strategic focus on developing treatments for rare cancers and enhancing its potential for accelerated regulatory approval.